This post elaborates on the ideas from a recent freely-available commentary published in the journal Addiction.
Accessing opioid agonist therapy (OAT) and maintaining good adherence faces many barriers which can be geographical, financial, regulatory, situational or logistic. In some settings, lack of services hinders access to treatment for people living with opioid use disorder (OUD). In other settings—even where health‐care and medications are provided free of charge—many people who have OUD do not seek OAT. In the United States, recent ‘estimates suggest a gap between treatment need and capacity of 1.4 and 1.3 million in 2012, respectively’ . The ongoing epidemic of OUD needs to develop strategies to recruit and keep patients on OAT.
Some things in academia can become so much fabric of your life that you stop counting years. The conference of the College on Problems of Drug Dependence (CPDD) is one of those things. With the 2020 conference coming up soon, this blog summarises my annotated posters presented over eight years. (more…)
So what has the Cochrane membership done for me? Inspired by Dr Jeremy Grimshaw’s question: “So what has the Cochrane Collaboration ever done for us?” I submit a report card, a mosaic of my previous blogs, on my first 10 years with Cochrane.
Researchers recently found that many people with co-occurring mental health and substance use disorders are admitted to inpatient psychiatric units. According to a 2019 report from the Boston’s Institute for Healthcare Improvement and The Grayken Center, “hospitals have the opportunity to make a major impact in reducing morbidity and mortality related to opioid use.” The present study, therefore, looked at patients admitted to an acute care hospital in Vancouver, British Columbia. It sought to improve our understanding of this population and the care provided so that we can improve patients’ outcomes and care experiences.